Tagged with BD

Saudi Arabia Karim Smaira and Kamel Ghammachi, founders of Genpharm, underscores the strategic significance of the recent majority acquisition by Abdul Latif Jameel Health, part of Abdul Latif Jameel, driven by a shared vision and the imperative for accelerated growth. They discuss their expansion into diverse therapeutic areas, emphasizing the importance of…

South Korea ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and medical aesthetics. He walks us through ExoCoBio’s exosome-based finished product line as well as its promising preclinical findings not just…

Turkey Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare reforms and increased government support. According to a new report from Invest in Turkeye, in 2020 the country accounted for…

Turkey When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in new technology and increase their manufacturing capacity. A few multinational innovators took the opportunity to invest in their own plants,…

Turkey In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having their own plant or partnering with a local CMO provider – although all of them appear to agree on one…

Turkey Boehringer Ingelheim (BI), the largest private pharma company in the world, has become the latest Big Pharma player to commit to Turkish localization after announcing a contract manufacturing partnership with Abdi Ibrahim, the country’s national pharma champion.   The plan is to produce one out of every two boxes of…

Turkey Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies interested in Turkey, and the objective of reaching one billion dollars in revenue. In addition, he outlines Abdi’s international ambitions…

Turkey When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey’s pharma industry; the first time a Turkish firm had ever taken part in the management of a European company.   With this partnership agreement, the long trend…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Opinion Becton Dickinson’s Fiona Garín looks at the rise of Healthcare-Acquired Infections (HAIs) in Europe and how an industry-wide culture of safety needs to be developed to counter this growing threat.   Healthcare systems in Europe are becoming more complex in their quest to drive affordability, quality of care and patient…

Puerto Rico With four manufacturing plants in three sites, Becton, Dickinson and Company is a symbol of the Puerto Rico’s manufacturing prowess. José Sánchez, director of Reagent Manufacturing and operations manager for BD’s Cayey site, discusses the company’s 62-year history on the island and explains why it continues to be an attractive…

Cannabis GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing a trail for other pharmaceutical companies to follow.   With more and more countries moving to legalise medical cannabis and…